المؤلفون: Jessica Ngo, Molly L. Tanenbaum, Korey K. Hood, Danielle Hessler, Marina Basina, Bruce A. Buckingham, Sarah Hanes, David M. Maahs, Shelagh A. Mulvaney

المصدر: Diabetes Technol Ther

مصطلحات موضوعية: Adult, Blood Glucose, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, MEDLINE, Pilot Projects, Telehealth, Young Adult, Endocrinology, Diabetes mellitus, Intervention (counseling), medicine, Humans, Hypoglycemic Agents, Glycemic, Type 1 diabetes, Continuous glucose monitoring, business.industry, Blood Glucose Self-Monitoring, Original Articles, medicine.disease, Telemedicine, Health care delivery, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Emergency medicine, Feasibility Studies, Female, business

الوصف: Background: Continuous glucose monitoring (CGM) can improve glycemic control for adults with type 1 diabetes (T1D) but certain barriers interfere with consistent use including cost, data overload, alarm fatigue, physical discomfort, and unwanted social attention. This pilot study aimed to examine feasibility and acceptability of a behavioral intervention, ONBOARD (Overcoming Barriers and Obstacles to Adopting Diabetes Devices) to support adults with T1D in optimizing CGM use. Methods: Adults (18–50 years) with T1D in their first year of CGM use were invited to participate in a tailored, multicomponent telehealth-based intervention delivered over four 60-min sessions every 2–3 weeks. Participants completed surveys (demographics; diabetes distress, Diabetes Distress Scale for adults with type 1 diabetes; satisfaction with program) and provided CGM data at baseline and postintervention (3 months). Data were analyzed using paired t-tests and Wilcoxon signed-rank tests. Results: Twenty-two participants (age = 30.95 ± 8.32 years; 59% women; 91% non-Hispanic; 86% White, 5% Black, 9% other; 73% pump users) completed the study. ONBOARD demonstrated acceptability and a high rate of retention. Moderate effect sizes were found for reductions in diabetes distress (P = 0.01, r = −0.37) and increases in daytime spent in target range (70–180 mg/dL: P = 0.03, r = −0.35). There were no significant increases in hypoglycemia. Conclusions: Findings show preliminary evidence of feasibility, acceptability, and efficacy of ONBOARD for supporting adults with T1D in optimizing CGM use while alleviating diabetes distress. Further research is needed to examine ONBOARD in a larger sample over a longer period.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a95cca377b873d1a44b4e4450a7680Test
https://pubmed.ncbi.nlm.nih.gov/34270351Test

المؤلفون: Marc D. Breton, Michael Pajewski, Charlotte L. Barnett, Basak Ozaslan, Nitchakarn Laichuthai, Mary C. Oliveri, Patricio Colmegna, Sue A. Brown, Jose Garcia-Tirado, Chaitanya L.K. Koravi, John P. Corbett, Helen E. Myers

المصدر: Diabetes Technol Ther

مصطلحات موضوعية: Adult, Blood Glucose, Pancreas, Artificial, medicine.medical_specialty, genetic structures, Endocrinology, Diabetes and Metabolism, Physical activity, 030209 endocrinology & metabolism, Hypoglycemia, Artificial pancreas, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Insulin Infusion Systems, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Exercise, Glycemic, Type 1 diabetes, Cross-Over Studies, business.industry, Original Articles, Middle Aged, medicine.disease, Anticipation, Intensity (physics), Medical Laboratory Technology, Diabetes Mellitus, Type 1, Cardiology, business

الوصف: Objective: Physical activity is a major challenge to glycemic control for people with type 1 diabetes. Moderate-intensity exercise often leads to steep decreases in blood glucose and hypoglycemia that closed-loop control systems have so far failed to protect against, despite improving glycemic control overall. Research Design and Methods: Fifteen adults with type 1 diabetes (42 ± 13.5 years old; hemoglobin A(1c) 6.6% ± 1.0%; 10F/5M) participated in a randomized crossover clinical trial comparing two hybrid closed-loop (HCL) systems, a state-of-the-art hybrid model predictive controller and a modified system designed to anticipate and detect unannounced exercise (APEX), during two 32-h supervised admissions with 45 min of planned moderate activity, following 4 weeks of data collection. Primary outcome was the number of hypoglycemic episodes during exercise. Continuous glucose monitor (CGM)-based metrics and hypoglycemia are also reported across the entire admissions. Results: The APEX system reduced hypoglycemic episodes overall (9 vs. 33; P = 0.02), during exercise (5 vs. 13; P = 0.04), and in the 4 h following (2 vs. 11; P = 0.02). Overall CGM median percent time 180 mg/dL (18.5% vs. 16.6%, P = 0.15). Overnight control was notable for both systems with no hypoglycemia, median percent in time 70–180 mg/dL at 100% and median percent time 70–140 mg/dL at ∼96% for both. Conclusions: A new closed-loop system capable of anticipating and detecting exercise was proven to be safe and feasible and outperformed a state-of-the-art HCL, reducing participants' exposure to hypoglycemia during and after moderate-intensity physical activity. ClinicalTrials.gov NCT03859401.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1ebe92c04b92b0b493f7ba474d498b3Test
https://pubmed.ncbi.nlm.nih.gov/33270531Test

المؤلفون: Melanie B. Gillingham, Corby K. Martin, Susana R Patton, Mark A. Clements, Roy W. Beck, Robin L. Gal, Jessica R. Castle, Peter G. Jacobs, Francis J. Doyle, Peter Calhoun, Zoey Li, Michael R. Rickels, Eyal Dassau, Michael C. Riddell

المصدر: Diabetes Technol Ther

مصطلحات موضوعية: Adult, Blood Glucose, medicine.medical_specialty, endocrine system diseases, Adolescent, Endocrinology, Diabetes and Metabolism, Physical activity, 030209 endocrinology & metabolism, Hypoglycemia, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Diabetes mellitus, Internal medicine, Medicine, Humans, 030212 general & internal medicine, Study analysis, Glycemic, Aged, Glycated Hemoglobin, Type 1 diabetes, business.industry, Continuous glucose monitoring, Blood Glucose Self-Monitoring, Original Articles, Middle Aged, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Glucose, business

الوصف: Objective: This study analysis was designed to examine the 24-h effects of exercise on glycemic control as measured by continuous glucose monitoring (CGM). Methods: Individuals with type 1 diabetes (ages: 15–68 years; hemoglobin A1c: 7.5% ± 1.5% [mean ± standard deviation (SD)]) were randomly assigned to complete twice-weekly aerobic, high-intensity interval, or resistance-based exercise sessions in addition to their personal exercise sessions for a period of 4 weeks. Exercise was tracked with wearables and glucose concentrations assessed using CGM. An exercise day was defined as a 24-h period after the end of exercise, while a sedentary day was defined as any 24-h period with no recorded exercise ≥10 min long. Sedentary days start at least 24 h after the end of exercise. Results: Mean glucose was lower (150 ± 45 vs. 166 ± 49 mg/dL, P = 0.01), % time in range [70–180 mg/dL] higher (62% ± 23% vs. 56% ± 25%, P = 0.03), % time >180 mg/dL lower (28% ± 23% vs. 37% ± 26%, P = 0.01), and % time

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f946197bfea403ea0c93b3653446d23Test
https://pubmed.ncbi.nlm.nih.gov/33259257Test

المؤلفون: Harsimran Singh, Jordan E. Pinsker, Alexandra Constantin, Molly McElwee Malloy, Lars Müller, Michelle L. Manning, Steph Habif, Scott Leas

المصدر: Diabetes Technology & Therapeutics

مصطلحات موضوعية: Insulin pump, Adult, Blood Glucose, Male, medicine.medical_specialty, Technology, Adolescent, Endocrinology, Diabetes and Metabolism, Control (management), 030209 endocrinology & metabolism, Artificial pancreas, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Insulin Infusion Systems, Glycemic control, Quality of life, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Patient Reported Outcome Measures, Glycemic, Type 1 diabetes, Patient-reported outcomes, business.industry, Blood Glucose Self-Monitoring, Original Articles, Middle Aged, medicine.disease, United States, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Automated insulin delivery, Physical therapy, Quality of Life, Female, business, Psychosocial

الوصف: Background: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. Methods: Individuals with type 1 diabetes (T1D) (≥14 years of age) who had ≥21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). Patient-reported outcomes (PROs) and glycemic outcomes were reviewed at each timepoint. Results: Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect® web application. Time in range was 78.2% (70.2%-85.1%) at T1 and 79.2% (70.3%-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the continuous glucose monitoring system as being valuable features of the system. Conclusions: Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended TIR glycemic outcomes in people with T1D.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd1ed23002c75a4f06c80aae7ed04a4Test
https://pubmed.ncbi.nlm.nih.gov/32846114Test

المؤلفون: Yogish C, Kudva, Lori M, Laffel, Sue A, Brown, Dan, Raghinaru, Jordan E, Pinsker, Laya, Ekhlaspour, Carol J, Levy, Laurel H, Messer, Boris P, Kovatchev, John W, Lum, Roy W, Beck, Linda, Gonder-Frederick, Thomas, Eggerman

المصدر: Diabetes Technol Ther

مصطلحات موضوعية: Adult, Blood Glucose, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Physical medicine and rehabilitation, Insulin Infusion Systems, Randomized controlled trial, law, Diabetes mellitus, Medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Patient Reported Outcome Measures, urogenital system, business.industry, Blood Glucose Self-Monitoring, Original Articles, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, business, Closed loop

الوصف: Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other glucose metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported glucose control outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported outcomes (PROs) in this iDCL trial. Methods: Participants were randomized 2:1 to CLC (N = 112) versus SAP (N = 56) and completed questionnaires, including Hypoglycemia Fear Survey, Diabetes Distress Scale (DDS), Hypoglycemia Awareness, Hypoglycemia Confidence, Hyperglycemia Avoidance, and Positive Expectancies of CLC (INSPIRE) at baseline, 3, and 6 months. CLC participants also completed Diabetes Technology Expectations and Acceptance and System Usability Scale (SUS). Results: The Hypoglycemia Fear Survey Behavior subscale improved significantly after 6 months of CLC compared with SAP. DDS did not differ except for powerless subscale scores, which worsened at 3 months in SAP. Whereas Hypoglycemia Awareness and Hyperglycemia Avoidance did not differ between groups, CLC participants showed a tendency toward improved confidence in managing hypoglycemia. The INSPIRE questionnaire showed favorable scores in the CLC group for teens and parents, with a similar trend for adults. At baseline and 6 months, CLC participants had high positive expectations for the device with Diabetes Technology Acceptance and SUS showing high benefit and low burden scores. Conclusion: CLC improved some PROs compared with SAP. Participants reported high benefit and low burden with CLC. Clinical Trial Identifier: NCT03563313.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26adc1eee24029fb9c7e86b3161320a8Test
https://pubmed.ncbi.nlm.nih.gov/34115959Test

المؤلفون: Timothy S. Bailey, William H. Polonsky, Phillip Banks, Vijay N. Joish, John B. Buse, Sophie Guillonneau, Thomas Danne, Michael J Davies, Frank J. Snoek, Sangeeta Sawhney, Dee Lin, Pablo Lapuerta, M. Reaney, Marion Afonso

المساهمون: Medical psychology, APH - Health Behaviors & Chronic Diseases, APH - Mental Health, Amsterdam Reproduction & Development (AR&D), Medical Psychology

المصدر: Danne, T, Joish, V N, Afonso, M, Banks, P, Sawhney, S, Lapuerta, P, Davies, M J, Buse, J B, Lin, D, Reaney, M, Guillonneau, S, Snoek, F J, Bailey, T S & Polonsky, W H 2021, ' Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone ', Diabetes Technology and Therapeutics, vol. 23, no. 1, pp. 70-77 . https://doi.org/10.1089/dia.2020.0068Test
Diabetes Technology and Therapeutics, 23(1), 70-77. Mary Ann Liebert Inc.
Diabetes technology & therapeutics, 23(1), 70-77. Mary Ann Liebert Inc.

مصطلحات موضوعية: Adult, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Diabetes Distress Scale, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Double-Blind Method, Diabetes mellitus, Internal medicine, Sotagliflozin, Medicine, Humans, Hypoglycemic Agents, Insulin, In patient, 030212 general & internal medicine, Glycosides, Patient Reported Outcome Measures, Glycemic, Type 1 diabetes, Patient-reported outcomes, business.industry, medicine.disease, Diabetes Treatment Satisfaction Questionnaire status version, Medical Laboratory Technology, Distress, Diabetes Mellitus, Type 1, Drug Therapy, Combination, business

الوصف: Background: Diabetes-related distress is common among persons affected by diabetes and is associated with suboptimal glycemic control and complications, thus constituting a relevant patient-report outcome (PRO). Improving glycemic control may reduce diabetes distress and improve treatment satisfaction. This post hoc analysis evaluated PRO data for a pooled cohort of adults with type 1 diabetes (T1D) receiving sotagliflozin as adjunct to optimized insulin in the inTandem1 and inTandem2 studies. Methods: Clinically meaningful changes in the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) and the two-item Diabetes Distress Scale (DDS2) total and individual scores were examined in the pooled data from the first 24 weeks of the studies. Results: In the cohort of patients with a baseline DTSQs total score ?32 (?76% of entire cohort), nearly twice as many patients treated with sotagliflozin 200 (45.9%) or 400 mg (42.3%) experienced a >3-point improvement from baseline versus those treated with placebo (24%). Treatment with sotagliflozin led to statistically significant (P < 0.05) improvements across all DTSQs items. Approximately 42% of all patients were considered to have a high risk of diabetes distress (total DDS2 score ?6) at baseline following insulin optimization. More patients shifted from high to low risk with sotagliflozin compared with placebo (?40% vs. 23%; P ? 0.0002). The baseline-Adjusted difference in DDS2 from placebo was significantly (P < 0.001) reduced by-0.5 and-0.6 for sotagliflozin 200 and 400 mg, respectively. Conclusions: Patients with T1D treated with sotagliflozin in addition to optimized insulin therapy reported meaningful improvements in treatment satisfaction and diabetes distress. NCT02384941 and NCT02421510

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad75f1ce2293246a899b5a67e1c12773Test
https://pubmed.ncbi.nlm.nih.gov/32721228Test

المؤلفون: Jake A. Kushner, Eda Cengiz, Paul Strumph, Bruce W. Bode, R. Paul Wadwa, Phillip Banks, Darren K. McGuire, Thomas Danne, Sangeeta Sawhney, Anne L. Peters

المصدر: Diabetes Technol Ther

مصطلحات موضوعية: Adult, Blood Glucose, Male, Pediatrics, medicine.medical_specialty, Diabetic ketoacidosis, endocrine system diseases, Adolescent, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, MEDLINE, 030209 endocrinology & metabolism, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Double-Blind Method, Diabetes mellitus, Medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Glycosides, Young adult, Glycated Hemoglobin, Type 1 diabetes, business.industry, Sotagliflozin, nutritional and metabolic diseases, Original Articles, medicine.disease, Medical Laboratory Technology, Increased risk, Diabetes Mellitus, Type 1, Drug Therapy, Combination, Female, business

الوصف: Background: Young adults with type 1 diabetes (T1D) tend to have higher A1C than older adults and are at increased risk for diabetic ketoacidosis (DKA). Oral adjuncts to insulin have not been previously studied in this population. Methods: In this phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, adults aged 18–30 years with T1D and A1C ≥9.0% were randomly assigned to placebo (n = 42) or sotagliflozin 400 mg (n = 43), in addition to insulin for 12 weeks. Insulin doses were adjusted to meet glucose targets (preprandial 80–130 mg/dL, postprandial

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af775ba686fa99a6689d067e4c6fb8d4Test
https://pubmed.ncbi.nlm.nih.gov/32640846Test

المؤلفون: Anne Fagot-Campagna, Christelle Gastaldi-Ménager, Lise Meunier, Coralie Amadou, A Aguade, Dorian Verboux, Yann Videau

المصدر: Diabetes technologytherapeutics. 23(1)

مصطلحات موضوعية: Insulin pump, Adult, Male, medicine.medical_specialty, genetic structures, Endocrinology, Diabetes and Metabolism, Population, MEDLINE, 030209 endocrinology & metabolism, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Insulin Infusion Systems, Sex Factors, Internal medicine, Diabetes mellitus, medicine, Humans, Insulin, 030212 general & internal medicine, education, Male gender, Type 1 diabetes, education.field_of_study, business.industry, Blood Glucose Self-Monitoring, Age Factors, medicine.disease, Population based study, Medical Laboratory Technology, Social deprivation, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Social Isolation, Female, business

الوصف: Objectives: The objective of this population-based study was to identify factors associated with insulin pump therapy initiation in adults with insulin-requiring diabetes in France in 2015. Method:...

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb8a752f43cbae5f9aa1150e5acace1Test
https://pubmed.ncbi.nlm.nih.gov/32522046Test

المؤلفون: Ella Zomer, Zanfina Ademi, Georgia Soldatos, Danny Liew, Sophia Zoungas, Arul Earnest, Anthony Pease

المصدر: Diabetes technologytherapeutics. 22(11)

مصطلحات موضوعية: Adult, Blood Glucose, medicine.medical_specialty, Cost effectiveness, Endocrinology, Diabetes and Metabolism, Cost-Benefit Analysis, 030209 endocrinology & metabolism, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Insulin Infusion Systems, Willingness to pay, Health care, Medicine, Humans, Insulin, 030212 general & internal medicine, health care economics and organizations, Glycemic, Type 1 diabetes, business.industry, Australia, Cost-effectiveness analysis, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Cohort, Emergency medicine, Quality-Adjusted Life Years, business, Decision analysis

الوصف: Background: Hybrid closed-loop systems may offer improved HbA1c levels, more time-in-range, and less hypoglycemia than alternative treatment strategies. However, it is unclear if glycemic improvements offset this technology's higher acquisition costs. Among adults with type 1 diabetes in Australia, we sought to evaluate the cost-effectiveness of a hybrid closed-loop system in comparison with the current standard of care, comprising insulin injections and capillary glucose testing. Methods: Cost-effectiveness analysis was performed using decision analysis in combination with a Markov model to simulate disease progression in a cohort of adults with type 1 diabetes and compare the downstream health and economic consequences of hybrid closed-loop therapy versus current standard of care. Transition probabilities and utilities were sourced from published studies. Costs were considered from the perspective of the Australian health care system. A lifetime horizon was considered, with annual discount rates of 5% applied to future costs and outcomes. Uncertainty was assessed with probabilistic and deterministic sensitivity analyses. Results: Use of a hybrid closed-loop system resulted in an incremental cost-effectiveness ratio of Australian dollars (AUD) 37,767 per quality-adjusted life year (QALY) gained. This is below the traditionally cited willingness to pay a threshold of $50,000 per QALY gained in the Australian setting. Sensitivity analyses that varied baseline glycemic control, treatment effects, technology costs, age, discount rates, and time horizon indicated the results to be robust. Conclusions: For adults with type 1 diabetes, hybrid closed-loop therapy is likely to be cost-effective compared with multiple daily injections and capillary glucose testing in Australia.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ebcb08ebaae33bcc0b6923337591db8Test
https://pubmed.ncbi.nlm.nih.gov/32348159Test

المؤلفون: Nick Oliver, Pau Herrero, Vanessa Moscardó, Monika Reddy, Nathan R. Hill, Pantelis Georgiou

المصدر: Diabetes Technol Ther

مصطلحات موضوعية: Adult, Blood Glucose, medicine.medical_specialty, endocrine system diseases, Glucose control, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Child, Glycated Hemoglobin, Type 1 diabetes, Continuous glucose monitoring, business.industry, Blood Glucose Self-Monitoring, Original Articles, medicine.disease, Hypoglycemia, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Discriminant, Cardiology, business

الوصف: Objective: Increasing use of continuous glucose monitoring (CGM) data has created an array of glucose metrics for glucose variability, temporal patterns, and times in ranges. However, a gold standard metric has not been defined. We assess the performance of multiple glucose metrics to determine their ability to detect intra- and interperson variability to determine a set of recommended metrics. Methods: The Juvenile Diabetes Research Foundation data set, a randomized controlled study of CGM and self-monitored blood glucose conducted in children and adults with type 1 diabetes (T1D), was used. To determine the ability of the evaluated glycemic metrics to discriminate between different subjects and attenuate the effect of within-subject variation, the discriminant ratio was calculated and compared for each metric. Then, the findings were confirmed using data from two other recent randomized clinical trials. Results: Mean absolute glucose (MAG) has the highest discriminant ratio value (2.98 [95% confidence interval {CI} 1.64–3.67]). In addition, low blood glucose index and index of glycemic control performed well (1.93 [95% CI 1.15–3.44] and 1.92 [95% CI 1.27–2.93], respectively). For percentage times in glucose target ranges, the optimal discriminator was percentage time in glucose target 70–180 mg/dL. Conclusions: MAG is the optimal index to differentiate glucose variability in people with T1D, and may be a complementary therapeutic monitoring tool in addition to glycated hemoglobin and a measure of hypoglycemia. Percentage time in glucose target 70–180 mg/dL is the optimal percentage time in range to report.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b044c7ac9ce208627f5be29c83ef5f4fTest
https://pubmed.ncbi.nlm.nih.gov/32163723Test